Company intelligence

Thyme Care

As of September 4, 2026, Thyme Care was last valued at $2 billion (September 2026 Series E) and has raised at least $220M in equity across 2 sourced funding rounds.

Last verified Sep 4, 2026

Thyme Care at a glance

As of
Latest valuation
$2 billion[1]
Series E · September 2026Derived
Equity raised
$220M[2]
Across 2 sourced roundsDerived
Lead investors
Morgan Health[3]
Series E · September 2026
  1. [1] Latest valuation: CNBC, September 4, 2026
  2. [2] Equity raised: Sum of the 2 sourced equity rounds in the funding history below (debt, tender offers and rumored rounds excluded), September 4, 2026
  3. [3] Lead investors: CNBC, September 4, 2026

What Thyme Care does

Thyme Care is a value-based cancer care company that works with health plans, employers and risk-bearing providers and takes on accountability for care quality, outcomes and total cost of care.[1] It combines a technology-enabled care team with integration into oncology practices to support patients through treatment.[1] The company was founded in 2020.[1] Its funding announcements are datelined Nashville, Tennessee.[1] As of September 2026, its services were available to more than 10.5 million people in all 50 states, and it managed more than $7 billion in oncology spending.[2] The company reports validated reductions of 5% to 10% in total cost of care.[2] Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital and a16z Bio + Health were among the participants.[2] Alongside the round it created a parent company, Thyme Companies, to build separate oncology businesses, starting with biosimilar adoption and clinical trial enrollment.[2]

Business model and customers

Thyme Care says it is profitable and generating positive free cash flow.[2]

Leadership

  • Co-founders Robin Shah and Dr. Bobby Green previously worked in community oncology practices and on national infrastructure at Flatiron Health and OneOncology.[1]
  • Robin Shah became executive chairman of Thyme Companies, while Brad Diephuis, M.D., runs Thyme Care as CEO and Green serves as president and chief medical officer.[2]

Is something wrong on this page?

Recent changes

  1. Sep 4, 2026Raised $125M Series E at a $2 billion valuation CNBC
  2. Sep 4, 2026First reported valuation: $2 billion CNBC
  3. Sep 4, 2026Thyme Care Doubles to $2B on Cancer Navigation Pulse story
  4. Jul 16, 2024Raised $95M Series C statnews.com

Funding history

2 equity events · newest first · sources dated per row
DateRoundAmountValuationLead investorsSource
Sep 4, 2026Series E$125M$2 billionpost-money
Morgan Healthunverified
CNBCPulse story
Jul 16, 2024Series C$95M—
—
statnews.com

Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

Funding timeline · 2 rounds · $220M tracked
$0.0M$70M$140M$95MSeries CJul 24$125MSeries ESep 26

How Thyme Care has been funded

In July 2024 it raised a $95 million Series C that included new investor Concord Health Partners and returning investors Town Hall Ventures, Andreessen Horowitz, Foresite Capital and CVS Health Ventures.[3] That round followed a $60 million Series B about a year earlier and brought total funding to $178 million.[3] A $97 million Series D in September 2025 added Morgan Health, Humana, Texas Oncology and Memorial Hermann Health System as investors and brought total capital raised to $275 million.[1] In September 2026 it raised more than $125 million in a Series E led by Morgan Health at a valuation above $2 billion.[2]

Investors

Latest Pulse

  1. This Week Showed AI Funding's Two Speeds at OnceStoke Space and Mistral raised a combined $4.2 billion this week while Sapien and NavigateAI, two real vertical-AI companies with paying customers, raised a combined fraction of that -- the same split Pulse has tracked in AI money all year.→
  2. The Application Layer Is Where I'd Be Writing ChecksNearly $5 billion went into three compute-layer companies in a single week while the software built on top of that compute raised a fraction of it -- and the compute bets are credit trades wearing venture clothes.→
  3. Why AI Compute Swallowed the Week's Venture DollarsCrusoe, Fluidstack and Gimlet Labs closed $4.8 billion between them in five days, and every dollar landed in the layer between the chips and the models rather than in the applications built on top.→
  4. Thyme Care Doubles to $2B on Cancer NavigationMorgan Health led a $125 million Series E with Humana and CVS Health Ventures joining, as the Nashville company's oncology navigation service reached 135,000 actively treated patients.→

Coverage Timeline

newest first
  1. Sep 4, 2026FUNDINGThyme Care Doubles to $2B on Cancer Navigation$125M Series E→

All Coverage

Related Companies

Thyme Care FAQ

What is Thyme Care's valuation?

In September 2026 it raised more than $125 million in a Series E led by Morgan Health at a valuation above $2 billion.[2]

Who founded Thyme Care?

Co-founders Robin Shah and Dr. Bobby Green previously worked in community oncology practices and on national infrastructure at Flatiron Health and OneOncology.[1]

What does Thyme Care do?

Thyme Care is a value-based cancer care company that works with health plans, employers and risk-bearing providers and takes on accountability for care quality, outcomes and total cost of care.[1]

How much has Thyme Care raised?

Thyme Care has raised at least $220M in equity across 2 sourced funding rounds tracked by Value Add VC. The most recent was a $125M Series E in September 2026 at a $2 billion post-money valuation, reported by CNBC. Debt financing, tender offers and secondary sales are not counted.

Who invested in Thyme Care?

Lead investors in Thyme Care's sourced funding rounds include Morgan Health. Per round: its September 2026 Series E was led by Morgan Health.

References

researched 2026-10-24
  1. Yahoo Finance
  2. Pulse 2.0
  3. statnews.com
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·